Free tool
FAERS Monitor: Hyrnuo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 219972 or its brand name (Hyrnuo, Sevabertinib). Reports on generic versions are filed under their own applications.
Reports
11
Serious
7
64% of reports
Hospitalization
2
Death reported
3
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea5
- disease progression2
- acute kidney injury1
- anaemia1
- csf test abnormal1
- defaecation urgency1
- drug ineffective1
- erythema1
- lung cancer metastatic1
- lung neoplasm malignant1
- metastases to central nervous system1
- oedema1
- pneumonia1
- product dose omission issue1
- product use in unapproved indication1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2025 | 1 |
| 2026 | 10 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,148 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| csf test abnormal | 1 | 3812.8 | 587.1 | 950 |
| lung cancer metastatic | 1 | 663.7 | 102.4 | 165 |
| defaecation urgency | 1 | 272.9 | 42.1 | 67 |
| metastases to central nervous system | 1 | 148.3 | 22.9 | 36 |
| lung neoplasm malignant | 1 | 46.5 | 7.2 | 11 |
| oedema | 1 | 35.3 | 5.4 | 8 |
| disease progression | 2 | 32.3 | 9.2 | 34 |
| diarrhoeaSignal | 5 | 14.8 | 7.8 | 53 |
| acute kidney injury | 1 | 12.5 | 1.9 | 2 |
| anaemia | 1 | 10.0 | 1.5 | 2 |
| erythema | 1 | 9.3 | 1.4 | 1 |
| product use in unapproved indication | 1 | 7.7 | 1.2 | 1 |
| product dose omission issue | 1 | 6.5 | 1.0 | 1 |
| pneumonia | 1 | 5.9 | 0.9 | 1 |
| drug ineffective | 1 | 1.5 | 0.2 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.